Moolec Science, a Pioneer in Molecular Farming and Food

- Moolec Science Ltd. (“Moolec”) and LightJump Acquisition Corp. (“LightJump”), a particular function acquisition firm, have entered right into a definitive enterprise mixture settlement. The transaction units Moolec’s proforma fairness worth at $504 million, assuming no redemptions from shareholders of LightJump. Upon closing, the mixed firm is anticipated to be listed on Nasdaq below the ticker image “MLEC”.
- Moolec, a science-based meals ingredient firm, focuses on growing actual animal proteins in vegetation utilizing Molecular Farming, a scalable, reasonably priced, and sustainable expertise which is the manufacturing of animal proteins utilizing vegetation as small factories. The corporate’s product portfolio and pipeline leverages the agronomic effectivity of broadly used goal crops, like soybeans and peas. Moolec targets the fast-growing various proteins market development.
- Moolec holds a rising worldwide patent portfolio for its Molecular Farming expertise. Its first two merchandise – plant-based dairy ingredient chymosin and dietary oil GLA, each utilizing safflower as a provider crop – have achieved regulatory clearance and seed stock scale-up actions had been carried out in 2022, accelerating the event of soy and pea-based merchandise designed to interchange meat.
- Moolec is backed by Nasdaq-listed Bioceres Crop Options Corp. (NASDAQ: BIOX), a completely built-in supplier of crop productiveness options enabling the transition to a carbon impartial agriculture; Theo I, a life sciences enterprise capital enterprise; and Union Group, a non-public fairness administration agency.
- Moolec expects to turn into the primary Molecular Farming FoodTech firm to be listed on Nasdaq Change as a class creator of the choice protein panorama targeted on this expertise. The transaction is anticipated to shut within the second half of 2022.
WARWICK, United Kingdom, June 15, 2022 (GLOBE NEWSWIRE) — Moolec Science Ltd. (“Moolec Science”, “Moolec”), a science-based meals ingredient firm; and LightJump Acquisition Corp. (Nasdaq: LJAQ; “LightJump”), a publicly traded particular function acquisition firm, introduced at this time the entry right into a definitive settlement for a enterprise mixture that will lead to Moolec Science SA (the “Firm”), a newly created affiliate of Moolec included in Luxembourg, changing into a publicly listed firm. Pursuant to the transactions contemplated by the enterprise mixture settlement, Moolec and LightJump will in the end turn into wholly-owned subsidiaries of the Firm (the “Mixed Firm”). The transaction is anticipated to be accomplished within the second half of 2022 and upon closing the Firm is anticipated to be listed on Nasdaq below the ticker image “MLEC”.
Moolec is a Molecular Farming pioneer within the new meals trade that makes use of vegetation to provide actual animal proteins. Molecular Farming allows the synthesis of actual animal proteins’ DNA in any seed crop, fastidiously choosing every protein for its capacity so as to add worth when it comes to a focused performance trait corresponding to clotting, style, texture, or dietary worth. The ensuing proteins can then be used as elements in client meals merchandise offering tastier, extra practical, and reasonably priced animal-free protein alternate options.
Molecular Farming is exclusive in its capacity to capitalize on the dimensions that in depth agriculture entails to attain affordability. Additionally it is price environment friendly as a result of it leverages biology, utilizing vegetation and their inputs – solar, water, and soil – as small factories for the manufacturing of animal proteins. The vegetation are grown by conventional farming practices that lead to economies of scale by excessive productiveness quantity manufacturing.
The Firm’s first two merchandise are Chymosin SPC, a bovine protein expressed in safflower that has curdling functions within the cheese trade, and gamma-linoleic acid (GLA), a dietary oil expertise sourced from Bioceres Crop Options. Each merchandise have been cleared by regulatory authorities and the Firm is at present ramping up seed inventories. Upon completion of nook stone milestones in these two merchandise, Moolec has accelerated product improvement efforts to widen its expertise attain, by utilizing the 2 crops which can be most broadly used as protein alternate options – soy and peas – to develop precise meat proteins.
As well as, Moolec’s Molecular Farming platform has the potential to switch and improve different vegetation utilizing animal proteins, which may enable the Firm to probably think about different market alternatives. Such attainable market alternatives embody milk, egg, hen and fish replacements, or different various biomaterials and cosmetics.
“Moolec Science is a class creator within the various protein panorama. Our Molecular Farming expertise focuses on offering actual animal proteins with out utilizing any animals, primarily based on the genetic engineering of seeds to provide proteins the identical method animals do,” mentioned Gastón Paladini, Chief Government Officer and Co-Founder. “As fourth technology of a household enterprise that is without doubt one of the largest meat gamers within the Southern Cone, I’ve first-hand information of the challenges confronted by the trade. Moolec’s purpose is to make use of science in meals to beat present world meals safety points, constructing a extra sustainable, resilient, and equitable meals system.”
“LightJump Acquisition Corp. is worked up to be partnering with Moolec Science, a FoodTech pioneer in Molecular Farming,” mentioned Robert Bennett, Chief Government Officer of LightJump Acquisition Corp. “We consider Moolec’s differentiated expertise platform will have the ability to tackle the worldwide rising demand for animal proteins, whereas delivering them at a small fraction of the associated fee and environmental affect of current approaches. We’re dedicated to working alongside Moolec’s excellent administration staff to help its growth plans and its transition to changing into a Nasdaq-listed firm.”
“Bioceres Crop Options’ mission is to develop and produce to market applied sciences that may assist agriculture transition in direction of carbon neutrality. We need to do that whereas growing productiveness, in order that defending our planet doesn’t come at a value to farmers or customers. On this quest, we have now developed distinctive applied sciences for drought tolerance and biologically enhanced vitamin, safety, and well being for a number of main crops. Now, that is solely a part of the reply. Preserving assets can be about doing extra with what’s at present being produced, and right here is the place molecular farming could be very highly effective. Moolec is main this life sciences’ class by engineering soybeans and different crops to instantly produce key animal proteins, getting us a step nearer to the place we must be,” mentioned Federico Trucco, Bioceres Crop Options’ CEO.
Transaction Overview
The Moolec Science LightJump Acquisition Corp. enterprise mixture units the Firm’s proforma fairness worth at $504 million. Because of the transaction, the Mixed Firm is anticipated to be funded with $138 million money held in LightJump’s belief account, assuming no LightJump shareholders train their redemption rights at closing and earlier than fee of transaction bills. As well as, LightJump has entered right into a backstop settlement with entities affiliated with Moolec to ensure a minimal of $10 million at closing.
Beneath the phrases of the proposed transaction: (i) the present shareholders of Moolec will contribute all of their shares of Moolec to the Firm in alternate for atypical shares of the Firm and (ii) LightJump will merge with a newly fashioned wholly owned subsidiary of the Firm and LightJump’s atypical shares and warrants will probably be exchanged for atypical shares and warrants of the Firm. This may lead to Moolec and LightJump being wholly owned subsidiaries of the Firm.
Money proceeds raised in reference to the transaction will primarily be used to speed up the commercialization of late-stage merchandise, Chymosin and GLA; growth of R&D & Regulatory Approval efforts for the prevailing product pipeline; funding for staff growth and common company bills; and natural & inorganic development alternatives.
The boards of administrators of LightJump and Moolec have authorized the proposed transaction. Completion of the proposed transaction is topic to shareholder approval of LightJump and different customary closing circumstances, together with a registration assertion being declared efficient by the U.S. Securities and Change Fee (the “SEC”). The transaction is anticipated to be accomplished within the second half of 2022.
On June 8, 2022, LightJump Acquisition Corp. filed with the SEC a preliminary proxy assertion in reference to a proposal to increase the date by which LightJump should consummate a enterprise mixture.
Extra details about the proposed transaction, together with a replica of the enterprise mixture settlement and investor presentation, will probably be supplied in a Present Report on Kind 8-Okay to be filed by LightJump Acquisition Corp. with the SEC and obtainable at www.sec.gov. As well as, LightJump intends to file a proxy assertion/registration assertion which is able to type a part of the Kind F-4 to be filed by the Firm with the SEC (the “Kind F-4”) and can file different paperwork relating to the proposed transaction with the SEC.
Advisors
EarlyBird Capital, a boutique funding financial institution, acted as monetary advisor to LightJump. Linklaters LLP acted as authorized counsel to Moolec, and Okay&L Gates LLP acted as authorized counsel to LightJump within the transaction.
Investor Convention Name Data
Moolec Science and LightJump Acquisition Corp. will host a joint investor convention name to debate the proposed transaction at this time, June 15, 2022 at 8:30 am ET. To hearken to the ready remarks through webcast, please go to www.lightjumpcap.com/investor-conference-call-video. A replay of the decision will probably be obtainable on the similar hyperlink in addition to on LightJump Acquisition Corp.’s web site at www.lightjumpcap.com by September 30, 2022, at 11:59 pm ET.
About LightJump Acquisition Corp.
LightJump is a Delaware clean examine firm included on July 28, 2020 fashioned for the aim of getting into right into a merger, share alternate, asset acquisition, inventory buy, recapitalization, reorganization or different related enterprise mixture with a number of goal companies. For extra data, go to www.lightjumpcap.com/lightjump-acquisition-corp.
About Moolec Science
Moolec is a science-based ingredient firm targeted on producing actual animal proteins in vegetation by Molecular Farming, a disruptive expertise within the various protein panorama. Its function is to improve style, vitamin, and affordability of other protein merchandise whereas constructing a extra sustainable and equitable meals system. The corporate’s technological strategy goals to have the associated fee construction of plant-based options with the organoleptic properties and performance of animal-based ones. Moolec’s expertise has been below improvement for greater than a decade and is thought for pioneering the manufacturing of a bovine protein in a crop for the meals trade. Moolec is run by a various staff of Ph.Ds and Meals Insiders, and operates in the US, Europe, and South America. For extra data, go to www.moolecscience.com.
Ahead Trying Statements
This press launch incorporates “forward-looking statements.” Ahead-looking statements could also be recognized by means of phrases corresponding to “forecast,” “intend,” “search,” “goal,” “anticipate,” “consider,” “count on,” “estimate,” “plan,” “outlook,” and “challenge” and different related expressions that predict or point out future occasions or traits or that aren’t statements of historic issues. For instance, statements regarding the following embody ahead trying statements: the expansion of Moolec’s enterprise and its capacity to appreciate anticipated outcomes; the enterprise mannequin of Moolec referring to any partnerships, business contracts, regulatory approvals or patent filings; the viability of its development and business technique; monetary projections; the success, price and timing of its product improvement skills; the benefits and potential of Moolec’s expertise and merchandise, together with compared to competing applied sciences and merchandise; traits and developments within the trade; the addressable market; the contemplated transaction amongst Moolec and LightJump; Moolec’s addressable market; and the potential results of the enterprise mixture amongst Moolec and LightJump. Such forward-looking statements with respect to efficiency, prospects, revenues, and different facets of the enterprise of Moolec or LightJump are predictions, projections and different statements about future occasions which can be primarily based on present expectations and assumptions and, in consequence, are topic to dangers and uncertainties. Though we consider that we have now an affordable foundation for every forward-looking assertion contained on this press launch, we warning you that these statements are primarily based on a mixture of information and elements, about which we can’t be sure. These elements embody, however should not restricted to: (1) the shortcoming to finish the transactions contemplated by the proposed enterprise mixture, ensuing within the Mixed Firm with the expectation to be listed on Nasdaq; (2) the shortcoming to acknowledge the anticipated advantages of the proposed enterprise mixture, which can be affected by, amongst different issues, competitors, and the power of the mixed enterprise to develop and handle development profitably; (3) the shortcoming to efficiently retain or recruits officers, key workers, or administrators following the proposed enterprise mixture; (4) results on LightJump’s public securities’ liquidity and buying and selling; (5) the market’s response to the proposed enterprise mixture; (6) the dearth of a marketplace for LightJump’s securities; (7) Moolec’s and LightJump’s monetary efficiency following the proposed enterprise mixture; (8) prices associated to the proposed enterprise mixture; (9) modifications in relevant legal guidelines or laws; (10) the chance that LightJump or Moolec could also be adversely affected by different financial, enterprise, and/or aggressive elements; (11) the danger that Moolec is unable to efficiently develop and commercialize Moolec’s services or products or expertise important delays; (12) the danger of product legal responsibility or regulatory lawsuits referring to Moolec’s services; (13) the danger that Moolec is unable to safe or defend its mental property; (14) the power to take care of the itemizing of LightJump’s securities on Nasdaq and (15) the power for the Firm’s securities to be authorized for itemizing on Nasdaq or if authorized, keep the itemizing. The foregoing record of things just isn’t full or exhaustive. You need to fastidiously think about the foregoing elements in addition to different dangers and uncertainties described within the “Danger Components” part of LightJump’s Annual Report on Kind 10-Okay, Quarterly Reviews on Kind 10-Q and within the remaining prospectus of LightJump associated to its preliminary public providing filed with the SEC. You also needs to fastidiously think about the opposite dangers and uncertainties indicated once in a while in paperwork filed or to be filed with the SEC by LightJump and the Kind F-4 and proxy assertion to be filed with the SEC by the Firm and LightJump. Ought to a number of of those dangers or uncertainties materialize, or ought to any of our assumptions show incorrect, precise outcomes might differ in materials respects from these projected in these forward-looking statements. We undertake no obligation to replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case, besides as could also be required below relevant securities legal guidelines. Accordingly, you shouldn’t put undue reliance on these statements.
Vital Extra Data Concerning the Transaction Will Be Filed With the SEC
In reference to the proposed transaction, the Firm is anticipated to file a registration assertion on Kind F-4 with the SEC that may embody a prospectus with respect to the Firm’s securities to be issued in reference to the proposed transaction and a proxy assertion with respect to the shareholder assembly of LightJump Acquisition Corp. to vote on the proposed transaction. Shareholders of LightJump Acquisition Corp. and different individuals are inspired to learn, when obtainable, the Kind F-4, together with the preliminary proxy assertion/prospectus and amendments thereto and the definitive proxy assertion/prospectus and paperwork included by reference therein in addition to different paperwork to be filed with the SEC in reference to the proposed transaction as a result of these paperwork will comprise vital details about LightJump Acquisition Corp., Moolec Science, and the proposed transaction. After the registration assertion is said efficient, the definitive proxy assertion/prospectus to be included within the registration assertion will probably be mailed to shareholders of LightJump Acquisition Corp. as of a file date to be established for voting on the proposed transaction. As soon as obtainable, shareholders of LightJump Acquisition Corp. can even have the ability to receive a replica of the F-4, together with the proxy assertion/prospectus, and different paperwork filed with the SEC with out cost, by directing a request to: 101 Natoma St., 2F, San Francisco, CA 94105. The preliminary and definitive proxy assertion/prospectus to be included within the registration assertion, as soon as obtainable, will also be obtained, with out cost, on the SEC’s web site www.sec.gov.
Individuals within the Solicitation
The Firm and Moolec Science and their respective administrators and govt officers could also be thought-about contributors within the solicitation of proxies with respect to the potential transaction described on this communication below the foundations of the SEC. Details about the administrators and govt officers of LightJump Acquisition Corp. and their possession is about forth in LightJump Acquisition Corp. ’s filings with the SEC, together with its Kind 10-Okay for the 12 months ended December 31, 2020 and subsequent filings below part 16 of the Change Act or on Kind 10-Q. Extra data relating to the individuals who might, below the foundations of the SEC, be deemed contributors within the solicitation of LightJump Acquisition Corp.’s shareholders in reference to the potential transaction will probably be set forth within the registration assertion containing the preliminary proxy assertion/prospectus when these are filed with the SEC. These paperwork can be found freed from cost on the SEC’s web site at www.sec.gov or by directing a request to: 101 Natoma St., 2F, San Francisco, CA 94105.
No Supply or Solicitation
This communication just isn’t a proxy assertion or solicitation of a proxy, consent or authorization with respect to any securities or in respect of the potential transaction and doesn’t represent a suggestion to promote or a solicitation of a suggestion to purchase any securities of Firm or Moolec Science, nor shall there be any sale of any such securities in any state or jurisdiction wherein such supply, solicitation or sale could be illegal previous to registration or qualification below the securities legal guidelines of such state or jurisdiction. No supply of securities shall be made besides by way of a prospectus assembly the necessities of the Securities Act.
Moolec Science Media Contacts
Moolec Science and LightJump Acquisition Corp. Investor Contact: